{"6.62":{"start":"6.62","dur":"10.17","text":"&gt;&gt;David Roberts: Perhaps now we can move to\nthe next agenda item, which is the new Cancer"},"16.79":{"start":"16.79","dur":"5.469","text":"Drugs Fund. This has been here before. It\nis not new news, but we have had the consultation,"},"22.26":{"start":"22.259","dur":"4.381","text":"and therefore I think the purpose of this\nis to review that consultation and then to"},"26.64":{"start":"26.64","dur":"6.39","text":"agree the specific way forward, in order that\nwe can give clarity to all stakeholders. Bruce,"},"33.03":{"start":"33.03","dur":"1.92","text":"I think you are providing the intro on this."},"34.95":{"start":"34.95","dur":"5.6","text":"&gt;&gt;Bruce Keogh: Thanks very much, Chair. I\nwill just start by giving a little bit of"},"40.55":{"start":"40.55","dur":"8.02","text":"context. Improving cancer care is an absolute\npriority for NHS England, and the reason for"},"48.57":{"start":"48.57","dur":"6.589","text":"that is that it touches the lives and families\nof so many citizens of this country."},"55.16":{"start":"55.159","dur":"6.58","text":"Globally and in the NHS, we have made a lot\nof progress over the last decade, but that"},"61.74":{"start":"61.739","dur":"5.801","text":"is dependent on access to the newest treatments\nand the most effective treatments, as quickly"},"67.54":{"start":"67.54","dur":"1.56","text":"as possible."},"69.10":{"start":"69.1","dur":"7.47","text":"So improving the Cancer Drugs Fund is one\nof our commitments. We have discussed this"},"76.57":{"start":"76.57","dur":"5.07","text":"at the Board in 2015 and, indeed, since then\nwe have had a National Audit Office report,"},"81.64":{"start":"81.64","dur":"8.24","text":"a Public Accounts Committee report and a Cancer\nTaskforce led by Harpal Kumar, all of which"},"89.88":{"start":"89.88","dur":"3.69","text":"suggested that we needed to improve the Cancer\nDrugs Fund."},"93.57":{"start":"93.57","dur":"6.35","text":"So in late 2014 I started discussions with\nthe charities, the Association of British"},"99.92":{"start":"99.92","dur":"6.72","text":"Pharmaceutical Industries, the Department\nof Health, NICE, the MHRA and others so that"},"106.64":{"start":"106.64","dur":"6.34","text":"we could start to think of a way forward for\nthe Cancer Drugs Fund."},"112.98":{"start":"112.98","dur":"5.67","text":"We got to a point of formal consultation in\nNovember 2015, and that consultation closed"},"118.65":{"start":"118.65","dur":"9.52","text":"on 11 February. During that time we had 286\nresponses, variably from the pharmaceutical"},"128.17":{"start":"128.17","dur":"5.75","text":"industry, patient groups and charities, people\nworking in the National Health Service and"},"133.92":{"start":"133.92","dur":"1.37","text":"individuals."},"135.29":{"start":"135.29","dur":"9.209","text":"Of course, we need time to fully process some\nof those, but there were three main themes"},"144.50":{"start":"144.499","dur":"4.3","text":"that seem to have emerged from the consultation.\nThe first is that there is general support"},"148.80":{"start":"148.799","dur":"7.511","text":"for a managed access process with clear entry\nand exit criteria into the Cancer Drugs Fund."},"156.31":{"start":"156.31","dur":"6.149","text":"The second is that there was a need for much\ngreater clarity on the operational detail,"},"162.46":{"start":"162.459","dur":"6.84","text":"and in particular for the mechanisms of financial\ncontrol. Thirdly, people wanted to be reassured"},"169.30":{"start":"169.299","dur":"6.61","text":"that we had clear details of transition to\nthe new Cancer Drugs Fund."},"175.91":{"start":"175.909","dur":"6.881","text":"Interestingly, and not surprisingly, there\nwere some contrasting views. People asked"},"182.79":{"start":"182.79","dur":"4.929","text":"whether the new Cancer Drugs Fund would lead\nto more or less access to cancer drugs, and"},"187.72":{"start":"187.719","dur":"6.291","text":"I will come back to that. There were also\nquestions raised about whether cancer should"},"194.01":{"start":"194.01","dur":"6.009","text":"have a special status, over and above treatments\nfor other conditions."},"200.02":{"start":"200.019","dur":"7.351","text":"The paper which is in front of you describes\nour response to the consultation. I think"},"207.37":{"start":"207.37","dur":"7.039","text":"I would like to start by drawing people&#39;s\nattention to the front page of the paper,"},"214.41":{"start":"214.409","dur":"5.69","text":"where we quite clearly state that, for patients,\nthe new, improved version of the Cancer Drugs"},"220.10":{"start":"220.099","dur":"6.06","text":"Fund will help provide faster access to the\nmost promising cancer treatments for our patients."},"226.16":{"start":"226.159","dur":"6.461","text":"Secondly, for taxpayers, the new Cancer Drugs\nFund will drive stronger value for money in"},"232.62":{"start":"232.62","dur":"9.819","text":"drugs expenditure. Finally, for drug companies\nwho are willing to price their products appropriately,"},"242.44":{"start":"242.439","dur":"7","text":"the Cancer Drugs Fund offers a new fast-track\nroute to NHS funding for drugs at the point"},"249.44":{"start":"249.439","dur":"4.64","text":"of market authorisation."},"254.08":{"start":"254.079","dur":"6.451","text":"The key elements of a managed access process\nare these, and I will go through them at a"},"260.53":{"start":"260.53","dur":"5.419","text":"relatively high level. Firstly, all new cancer\ndrugs will be referred to NICE for assessment."},"265.95":{"start":"265.949","dur":"3.201","text":"This is a new development."},"269.15":{"start":"269.15","dur":"6.9","text":"Secondly, the assessment will not simply be\nyes or no; there will be an option for a maybe"},"276.05":{"start":"276.05","dur":"6.41","text":"when there is some level of uncertainty about\nthe value proposition or effectiveness of"},"282.46":{"start":"282.46","dur":"3.6","text":"a given drug."},"286.06":{"start":"286.06","dur":"7.289","text":"Those drugs or indications which are regarded\nas a maybe will become candidates for the"},"293.35":{"start":"293.349","dur":"7.511","text":"new Cancer Drugs Fund, and entry into that\nwill be approved by a joint NHS\/NICE investment"},"300.86":{"start":"300.86","dur":"7.26","text":"group or committee. Once a drug has spent\ntime in the Cancer Drugs Fund and the uncertainty"},"308.12":{"start":"308.12","dur":"8.009","text":"has been resolved or enough data has been\ncollected, NICE will perform a final appraisal"},"316.13":{"start":"316.129","dur":"7.181","text":"and opine yes or no with respect to whether\nthat drug should move into routine commissioning."},"323.31":{"start":"323.31","dur":"4.99","text":"The end result of this means that flow through\nthe Cancer Drugs Fund, because there are clear"},"328.30":{"start":"328.3","dur":"10.329","text":"entry and exit criteria, will be greater and\nmore flexible than it is at the moment. However,"},"338.63":{"start":"338.629","dur":"6.76","text":"this does require NICE to work at a greater\nspeed than it has done in the past."},"345.39":{"start":"345.389","dur":"6.331","text":"To that end, it will produce draft guidance\non drugs before marketing authorisation, with"},"351.72":{"start":"351.72","dur":"8.879","text":"the aim of producing final guidance within\n90 days of marketing authorisation. That will"},"360.60":{"start":"360.599","dur":"6.151","text":"require additional resourcing, and we have\nreceived assurance from NICE that they will"},"366.75":{"start":"366.75","dur":"8.25","text":"be able to develop the capacity and capability\nto meet those particular challenges."},"375.00":{"start":"375","dur":"9.05","text":"The new Cancer Drugs Fund will go live on\n1st July this year, not on 1st April. This"},"384.05":{"start":"384.05","dur":"9.679","text":"will give us time to resolve a number of issues.\nFirstly, the practical aspects of NICE publishing"},"393.73":{"start":"393.729","dur":"4.18","text":"initial recommendations prior to marketing\nauthorisation."},"397.91":{"start":"397.909","dur":"8.741","text":"Secondly, to enable us to address the risk\nof funding ineffective treatments during transition."},"406.65":{"start":"406.65","dur":"8.44","text":"Thirdly, how we can treat rare cancers and\noff-label drugs fairly. It is likely that"},"415.09":{"start":"415.09","dur":"7.979","text":"those particular drug and indication combinations\nwill be associated with greater uncertainty,"},"423.07":{"start":"423.069","dur":"4.981","text":"so that is likely to give them much greater\naccess into the Cancer Drugs Fund, which is"},"428.05":{"start":"428.05","dur":"4","text":"different from the position that we find ourselves\nin at the moment where they are often crowded"},"432.05":{"start":"432.05","dur":"5.209","text":"out by more expensive drugs for more common\nconditions."},"437.26":{"start":"437.259","dur":"9.791","text":"Finally, it will give us time to resolve the\nissue of whether we simply keep drugs in the"},"447.05":{"start":"447.05","dur":"7.97","text":"fund long enough to resolve the uncertainty,\nor whether we aim to keep drugs in the fund"},"455.02":{"start":"455.02","dur":"5.389","text":"in a way that gives maximum access to maximum\npatients. I would refer people to the third"},"460.41":{"start":"460.409","dur":"6.53","text":"bullet point at paragraph 17 for that particular\nissue."},"466.94":{"start":"466.939","dur":"7.76","text":"So on 1 April this year we will close the\ncurrent Cancer Drugs Fund, but roll drugs"},"474.70":{"start":"474.699","dur":"7.75","text":"over. Drugs that are in the Cancer Drugs Fund\nwill remain in it until they have been through"},"482.45":{"start":"482.449","dur":"11.481","text":"a final appraisal process by NICE. We also\nneed to sort out transitional funding arrangements."},"493.93":{"start":"493.93","dur":"5.509","text":"Those will be delegated, as you will see towards\nthe end of the paper, to the Chief Executive,"},"499.44":{"start":"499.439","dur":"8.421","text":"the Chief Financial Officer and myself. We\nare clear that we will anticipate seeing reimbursement"},"507.86":{"start":"507.86","dur":"24.919","text":"for these drugs \nat or below the rates which are in place in\nMarch 2016. We also need to ensure that we"},"532.78":{"start":"532.779","dur":"6.781","text":"keep the new Cancer Drugs Fund within a fixed\nbudget of \u00a3340 million."},"539.56":{"start":"539.56","dur":"7.7","text":"The methodology for controlling that expenditure\nhas been and may be described by the Chief"},"547.26":{"start":"547.26","dur":"7.24","text":"Financial Officer. So it seems to me that\nthe new operating model will remove some level"},"554.50":{"start":"554.5","dur":"2.51","text":"of uncertainty which currently exists."},"557.01":{"start":"557.01","dur":"5.8","text":"It will ensure that we are able to balance\nthe budget, and it will give patients clarity"},"562.81":{"start":"562.81","dur":"5.969","text":"about the status of any given drug or drug\ncombinations much sooner than the current"},"568.78":{"start":"568.779","dur":"2.141","text":"Cancer Drugs Fund does. Thank you."},"570.92":{"start":"570.92","dur":"3.229","text":"&gt;&gt;David Roberts: Simon, anything you want\nto add to this?"},"574.15":{"start":"574.149","dur":"5.88","text":"&gt;&gt;Simon Stevens: No. I think Bruce summarised\nit well. This is the substance of the discussion"},"580.03":{"start":"580.029","dur":"4.461","text":"we had very extensively prior to going out\nto consultation, with some important adjustments"},"584.49":{"start":"584.49","dur":"2.26","text":"made in the light of consultation."},"586.75":{"start":"586.75","dur":"3.24","text":"&gt;&gt;David Roberts: Okay, great. So, questions.\nVictor."},"589.99":{"start":"589.99","dur":"7.63","text":"&gt;&gt;Victor Adebowale: Just to be clear, will\nevery patient getting drugs under the current"},"597.62":{"start":"597.62","dur":"5.709","text":"fund continue to get drugs under the new regime?"},"603.33":{"start":"603.329","dur":"5.481","text":"&gt;&gt;Bruce Keogh: Just to be clear, the answer\nis yes."},"608.81":{"start":"608.81","dur":"0.82","text":"&gt;&gt;David Roberts: Unequivocally?"},"609.63":{"start":"609.63","dur":"1.1","text":"&gt;&gt;Bruce Keogh: Absolutely, Chair."},"610.73":{"start":"610.73","dur":"1.37","text":"&gt;&gt;David Roberts: Good. Okay. John."},"612.10":{"start":"612.1","dur":"3.53","text":"&gt;&gt;John Burn: We all knew, when the Cancer\nDrugs Fund was introduced that it was something"},"615.63":{"start":"615.63","dur":"5.53","text":"of an emergency measure and an emergency treatment,\nso this is actually a really impressive adaptation"},"621.16":{"start":"621.16","dur":"6.35","text":"and evolution of that into something that\nis much more adaptable to the needs of now."},"627.51":{"start":"627.51","dur":"3.79","text":"You said at the beginning that one of the\ncriticisms was that it still has the word"},"631.30":{"start":"631.3","dur":"5.539","text":"&#39;cancer&#39; on the front, and it is only one\nclass of disease, albeit one of our most pressing"},"636.84":{"start":"636.839","dur":"4.461","text":"ones. Noel and I sit on the accelerated access\nreview, which is looking at the broader picture"},"641.30":{"start":"641.3","dur":"4.18","text":"of how we get new, innovative treatments into\nthe Health Service."},"645.48":{"start":"645.48","dur":"6.719","text":"Can you just maybe connect those two together?\nHow does the accelerated access review connect"},"652.20":{"start":"652.199","dur":"4.7","text":"to this process? Is this informing that process,\nor will that process inform the further evolution"},"656.90":{"start":"656.899","dur":"1.611","text":"of the Cancer Drugs Fund?"},"658.51":{"start":"658.51","dur":"6.189","text":"&gt;&gt;Bruce Keogh: I think the Cancer Drugs Fund\nwill inform the accelerated access review."},"664.70":{"start":"664.699","dur":"7.95","text":"In May last year, I wrote to George Freeman\nindicating that we needed to link the two"},"672.65":{"start":"672.649","dur":"1.221","text":"processes."},"673.87":{"start":"673.87","dur":"7.25","text":"I think the issue which will influence that\nis the speed at which the accelerated access"},"681.12":{"start":"681.12","dur":"7.519","text":"review can come to its final conclusions,\nbut it is quite clear from their interim report"},"688.64":{"start":"688.639","dur":"2.26","text":"that the two are pretty well aligned."},"692.36":{"start":"692.36","dur":"5.38","text":"&gt;&gt;Noel Gordon: May I just say in passing,\nChairman, that this paper came through specialised"},"697.74":{"start":"697.74","dur":"6.649","text":"commissioning yesterday? Or course Sir John,\nwho is a real cancer expert, Margaret Casely"},"704.39":{"start":"704.389","dur":"6.45","text":"Hayford and myself put it under the expected\nchallenge and test of an assurance process."},"710.84":{"start":"710.839","dur":"5.18","text":"So I wanted to make the point that this has\nalready, in a sense, been battle-tested as"},"716.02":{"start":"716.019","dur":"2.721","text":"far as our assurance process is concerned."},"718.74":{"start":"718.74","dur":"10.519","text":"Bruce, the CDF as it is currently constituted\nworked for what I might call common conditions."},"729.26":{"start":"729.259","dur":"7.351","text":"How is it going to help with patients suffering\nfrom rarer cancer conditions?"},"736.61":{"start":"736.61","dur":"5.849","text":"&gt;&gt;Bruce Keogh: The way I see it working is\nthat the new Cancer Drugs Fund is largely"},"742.46":{"start":"742.459","dur":"10.521","text":"there to resolve issues of uncertainty related\nto the effectiveness of different drugs. In"},"752.98":{"start":"752.98","dur":"5.19","text":"the past, drugs for rare cancers have not\nbeen appraised by NICE."},"758.17":{"start":"758.17","dur":"4.27","text":"They will be appraised by NICE as part of\nthe new process. I think that will expose"},"762.44":{"start":"762.44","dur":"5.28","text":"that, in many cases, there are degrees of\nuncertainty, which I think is likely to lead"},"767.72":{"start":"767.72","dur":"6.669","text":"to much greater and easier access for those\nparticular drugs into the Cancer Drugs Fund."},"774.39":{"start":"774.389","dur":"13","text":"&gt;&gt;Moira Gibb: Bruce, this is not simple. It\nis often talked about in very simplistic terms,"},"787.39":{"start":"787.389","dur":"7.521","text":"though, in the media, so I would like something\nvery simple: how is this better for patients"},"794.91":{"start":"794.91","dur":"2.07","text":"than what we have now?"},"796.98":{"start":"796.98","dur":"9.26","text":"&gt;&gt;Bruce Keogh: I think it will provide faster\naccess for patients, and I think that is really"},"806.24":{"start":"806.24","dur":"8.42","text":"important. I think it will also bring clarity\nas to which drugs are the most effective drugs,"},"814.66":{"start":"814.66","dur":"5.739","text":"sooner than we know at the moment. I think\nthose are probably the two main things."},"820.40":{"start":"820.399","dur":"2.901","text":"&gt;&gt;Moira Gibb: Thank you."},"823.30":{"start":"823.3","dur":"8.519","text":"&gt;&gt;Bruce Keogh: May I just add one other point\nthat is quite important here? The current"},"831.82":{"start":"831.819","dur":"7.431","text":"Cancer Drugs Fund is full. What we have with\nthe new Cancer Drugs Fund is a system that"},"839.25":{"start":"839.25","dur":"3","text":"is much more fluid and much more flexible."},"842.25":{"start":"842.25","dur":"10.149","text":"We have clear entry and exit criteria, so\nwe can bring new drugs in with greater ease,"},"852.40":{"start":"852.399","dur":"4.87","text":"if you like, because we can get ineffective\ndrugs out, or drugs where the uncertainty"},"857.27":{"start":"857.269","dur":"5.171","text":"is resolved, or drugs which move into routine\ncommissioning earlier, in a way that we cannot"},"862.44":{"start":"862.44","dur":"3.269","text":"do quite as easily at the moment."},"865.71":{"start":"865.709","dur":"7.201","text":"&gt;&gt;Noel Gordon: Bruce, you mentioned in your\nintroduction the consultation process and"},"872.91":{"start":"872.91","dur":"2.45","text":"the 286 responses received."},"875.36":{"start":"875.36","dur":"6.399","text":"I was interested, as I was reading through\nthe additional papers that you provided here,"},"881.76":{"start":"881.759","dur":"8.32","text":"that of the overall number of respondents\nsomething like 34% declared having received"},"890.08":{"start":"890.079","dur":"7.531","text":"payment from drug companies and, a sub-category\nwithin that overall total being patients&#39;"},"897.61":{"start":"897.61","dur":"8.45","text":"and voluntary groups, 81% declared they had\nreceived drug company funding."},"906.06":{"start":"906.06","dur":"5.91","text":"Does that concern you in any way, particularly\nwith reference to our sunlight disclosure"},"911.97":{"start":"911.97","dur":"0.369","text":"programme?"},"912.34":{"start":"912.339","dur":"6.69","text":"&gt;&gt;Bruce Keogh: I think there are two things\nabout that. Firstly, you would expect a number"},"919.03":{"start":"919.029","dur":"7.021","text":"of the respondents to have interests in the\npharmaceutical industry, but the second thing"},"926.05":{"start":"926.05","dur":"5.75","text":"- and this is the most important point - is\nthat people have declared it."},"931.80":{"start":"931.8","dur":"6.64","text":"I think that is really important, because\nthat brings clarity to any potential conflicts"},"938.44":{"start":"938.44","dur":"4.86","text":"of interest or views that people might express."},"943.30":{"start":"943.3","dur":"9.039","text":"&gt;&gt;David Roberts: A couple of questions from\nme, if I may, Bruce. There was some suggestion"},"952.34":{"start":"952.339","dur":"6.461","text":"that a number of drugs - quite a significant\nproportion of the drugs - currently in the"},"958.80":{"start":"958.8","dur":"7.95","text":"CDF will not make it through the NICE evaluation\nor make it into routine commissioning."},"966.75":{"start":"966.75","dur":"7.639","text":"I just wonder what we think about that, and\nwhether you would agree with some of the external"},"974.39":{"start":"974.389","dur":"5.031","text":"reporting that has been done on this?"},"979.42":{"start":"979.42","dur":"6.709","text":"&gt;&gt;Bruce Keogh: We function in a tax-funded\nNational Health Service. We have an obligation,"},"986.13":{"start":"986.129","dur":"5.481","text":"I think, to get the best value for money for\ntaxpayers, who are also our patients."},"991.61":{"start":"991.61","dur":"5.12","text":"It is quite a - I was going to say it is a\nsimple formula, but it is not. The formula"},"996.73":{"start":"996.73","dur":"7.029","text":"which is applied is: how effective is a drug,\nand how much does it cost? Now, the efficacy"},"1003.76":{"start":"1003.759","dur":"1.221","text":"is pretty fixed."},"1004.98":{"start":"1004.98","dur":"4.93","text":"There is one component of that formula which\nis under the control of the pharmaceutical"},"1009.91":{"start":"1009.91","dur":"6.76","text":"companies, and that is the cost of the drug.\nBy influencing the cost of the drug, you can"},"1016.67":{"start":"1016.67","dur":"5.3","text":"influence the likelihood of that drug entering\nroutine commissioning."},"1021.97":{"start":"1021.97","dur":"5.59","text":"&gt;&gt;David Roberts: So we do not go into this\nwith any sort of firm, fixed view on this?"},"1027.56":{"start":"1027.56","dur":"4.95","text":"These are things that are still open for discussion\nat an appropriate time?"},"1032.51":{"start":"1032.51","dur":"1.46","text":"&gt;&gt;Bruce Keogh: Exactly."},"1033.97":{"start":"1033.97","dur":"6.89","text":"&gt;&gt;David Roberts: Good. Then the second thing\nis, within the consultation as I read it,"},"1040.86":{"start":"1040.86","dur":"11.09","text":"one of the most significant areas of concern\nis about the capacity and timeliness within"},"1051.95":{"start":"1051.95","dur":"8.14","text":"NICE to be able to do these reviews, which\nare intense, time-consuming, difficult and"},"1060.09":{"start":"1060.09","dur":"0.04","text":"so on."},"1060.13":{"start":"1060.13","dur":"5.32","text":"I think it would be appropriate for us to\nunderstand what assurances and what perspective"},"1065.45":{"start":"1065.45","dur":"4.63","text":"we may have on that, given it was one of the\nmost important aspects of the consultation?"},"1070.08":{"start":"1070.08","dur":"3.579","text":"&gt;&gt;Bruce Keogh: Well, the first thing I would\nsay is I think it has been a very legitimate"},"1073.66":{"start":"1073.659","dur":"5.041","text":"concern that people have expressed, and that\nwill have come from many different quarters,"},"1078.70":{"start":"1078.7","dur":"4.709","text":"not least of all patients who have to wait."},"1083.41":{"start":"1083.409","dur":"7.63","text":"So there are two things. Firstly, NICE needs\nto do more work and have greater capability"},"1091.04":{"start":"1091.039","dur":"5.62","text":"and capacity, and that requires resourcing,\nwhich Paul may want to say something about."},"1096.66":{"start":"1096.659","dur":"5.231","text":"However, the second thing - and this is the\nimportant thing - is that we have received"},"1101.89":{"start":"1101.89","dur":"6.63","text":"assurance from NICE that, with the appropriate\nresourcing, they can put that capability and"},"1108.52":{"start":"1108.52","dur":"1.17","text":"capacity in place."},"1109.69":{"start":"1109.69","dur":"5.03","text":"&gt;&gt;David Roberts: I understand their board\nis discussing this fairly soon, is that right?"},"1114.72":{"start":"1114.72","dur":"1.76","text":"&gt;&gt;Bruce Keogh: Yes. I think it is 17th March."},"1116.48":{"start":"1116.48","dur":"6.24","text":"&gt;&gt;David Roberts: Okay. Paul, you were nicely\nset up by your friend. Is there anything that"},"1122.72":{"start":"1122.72","dur":"0.959","text":"you would like to add?"},"1123.68":{"start":"1123.679","dur":"3.75","text":"&gt;&gt;Paul Baumann: Set up as usual. I think the\nassurances from NICE are the important part"},"1127.43":{"start":"1127.429","dur":"5.851","text":"of that. They have shared with us their very\nspecific resourcing plans around this, which"},"1133.28":{"start":"1133.28","dur":"4.54","text":"obviously are predicated on the forward pipeline\nthat we can see, and indeed the transitional"},"1137.82":{"start":"1137.82","dur":"1.56","text":"pipeline that we have."},"1139.38":{"start":"1139.38","dur":"4.45","text":"So I am very comfortable that they have considered\nthe correct volume of drugs, as far as we"},"1143.83":{"start":"1143.83","dur":"3.67","text":"can see that. They have worked out what the\nresource is that they need to live to the"},"1147.50":{"start":"1147.5","dur":"5.1","text":"standards that have been set in this. So I\nsee no reason for the Board to doubt the assurances"},"1152.60":{"start":"1152.6","dur":"1.5","text":"that we have been given."},"1154.10":{"start":"1154.1","dur":"4.13","text":"&gt;&gt;David Roberts: Therefore, Bruce, from a\nclinical perspective you are comfortable that"},"1158.23":{"start":"1158.23","dur":"4.46","text":"this is the best solution for the way forward,\nfor patients in particular?"},"1162.69":{"start":"1162.69","dur":"7.42","text":"&gt;&gt;Bruce Keogh: Yes, I am. I think this has\nbeen a comprehensive, complex process. Some"},"1170.11":{"start":"1170.11","dur":"8.46","text":"of the discussions have inevitably been difficult.\nHowever, I think there is a consensus view,"},"1178.57":{"start":"1178.57","dur":"6.03","text":"certainly among clinical colleagues, that\nwe have moved the dial and moved things forward."},"1184.60":{"start":"1184.6","dur":"4.12","text":"&gt;&gt;David Roberts: Paul, you are comfortable\nfrom a financial perspective as well that"},"1188.72":{"start":"1188.72","dur":"2.16","text":"this is the best alternative we can come up\nwith?"},"1190.88":{"start":"1190.88","dur":"1.2","text":"&gt;&gt;Paul Baumann: It is."},"1192.08":{"start":"1192.08","dur":"4.579","text":"&gt;&gt;David Roberts: You are comfortable, Noel,\nthat from SpecCom yesterday you gave this"},"1196.66":{"start":"1196.659","dur":"5.13","text":"a good working over, and the consultation\nhas been appropriately considered?"},"1201.79":{"start":"1201.789","dur":"5.201","text":"&gt;&gt;Noel Gordon: Yes. From both a design and\nimplementation perspective, I think we performed"},"1206.99":{"start":"1206.99","dur":"2.52","text":"a pretty rigorous assurance process yesterday."},"1209.51":{"start":"1209.51","dur":"7.45","text":"&gt;&gt;David Roberts: Okay. Any other final questions\nor comments? Simon, anything you would add?"},"1216.96":{"start":"1216.96","dur":"6.42","text":"&gt;&gt;Simon Stevens: No. Just to underline, we\nchartered an independent cancer taskforce"},"1223.38":{"start":"1223.38","dur":"5.2","text":"led by Sir Harpal Kumar, the chief executive\nof Cancer Research UK. Their clear recommendation"},"1228.58":{"start":"1228.58","dur":"4.57","text":"to us was to do what we are proposing this\nafternoon."},"1233.15":{"start":"1233.15","dur":"8.81","text":"Secondly, we have had a National Audit Office\nreview of the Cancer Drugs Fund Mark I, and"},"1241.96":{"start":"1241.96","dur":"6.469","text":"it clearly draws attention to the need to\nchange the way the CDF works. Thirdly, that"},"1248.43":{"start":"1248.429","dur":"7.221","text":"case was not only supported but accentuated\nby the Public Accounts Committee of the House"},"1255.65":{"start":"1255.65","dur":"3.04","text":"of Commons, who produced a report to that\neffect as well."},"1258.69":{"start":"1258.69","dur":"6.56","text":"So I think a combination of our cancer taskforce,\nthe National Audit Office in respect of the"},"1265.25":{"start":"1265.25","dur":"6.539","text":"good use of public resources, and Parliament\nthrough the PAC: this is going with the grain"},"1271.79":{"start":"1271.789","dur":"4.421","text":"of what people see as the sensible evolution\nof the Cancer Drugs Fund."},"1276.21":{"start":"1276.21","dur":"10.199","text":"&gt;&gt;David Roberts: Thank you. So now, I think,\nif there are no other questions or comments,"},"1286.41":{"start":"1286.409","dur":"8.361","text":"there are a series of recommendations and\nproposals that are made in paragraph 31. I"},"1294.77":{"start":"1294.77","dur":"4.69","text":"am not going to go through and read them all\nin individual glory, but can I take it from"},"1299.46":{"start":"1299.46","dur":"6.29","text":"our conversation that the Board is happy to\napprove the recommendations as set out in"},"1305.75":{"start":"1305.75","dur":"4.15","text":"the paper? Thank you very much."},"1309.90":{"start":"1309.9","dur":"5.159","text":"Bruce, I would like to say to Paul, and indeed\nto John, who is sitting next to you, that"},"1315.06":{"start":"1315.059","dur":"6.48","text":"this has been a considerable effort on all\npersons, and therefore please thank your teams"},"1321.54":{"start":"1321.539","dur":"5.89","text":"on behalf of this Board for their professionalism,\ntheir diligence and their effort and commitment"},"1327.43":{"start":"1327.429","dur":"4.561","text":"to what is a very important subject. Thank\nyou."}}